Grovet is moving! Due to the relocating, we will be closed from May 29 to May 31 2024. No orders will be processed or shipped during this period. However, it is possible to place your order. More information about the relocating, you can find here. If you have any questions or concerns, please do not hestitate to contact us at info@grovet.com.

Proteq West Nile 2x1 dose

SKU
126435
Marque:
Boehringer Ingelheim
Batch:
F22266
Expiry date:
25-Apr-2025
Numéro d'enregistrement:
NL: REG NL 107618

Le numéro d’autorisation de mise sur le marché de votre pays ne pas répertorié ? Il s'agit alors d'un produit cascade. Cliquez ici pour plus d'informations.

Active immunisation against West Nile virus.

Avertissement : le produit sur la photo peut différer du produit réel.

Proteq West Nile 2x1 dose + syringe

Suspension for injection containing West Nile recombinant canarypox virus (vCP2017). 

The vaccine strain vCP2017 is a recombinant canarypox virus expressing the preM/E genes of West Nile virus. After inoculation, the virus does not multiply in the horse but expresses the protective proteins. As a consequence, these proteins induce protective immunity against equine West Nile disease.

Indication
Active immunisation of horses from 5 months of age against West Nile disease. Proteq West Nile reduces the number of viraemic horses. If clinical signs are present, their duration and severity are reduced. 
Onset of immunity: 4 weeks after the first dose of the primary vaccination course. In order to achieve full protection, the full vaccination course of two doses must be given.  

Duration of immunity: 1 year after a full primary vaccination course of two injections.

Route of administation and dosage
For intramuscular use.
Shake gently before use. 

Administer one dose of 1ml, by intramuscular injection, preferably in the neck region, according to the following schedule:
- Primary vaccination course: first injection from 5 months of age, second injection 4-6 weeks later
- Revaccination: a sufficient degree of protection should be achieved after an annual booster injection with a single dose although this schedule has not been fully validated.

© 2024 Grovet B.V. All rights reserved.